Double COVID jab seems to curb Delta variant: EMA
ETX Studio
Julai 2, 2021 10:12 MYT
Julai 2, 2021 10:12 MYT
Lab tests also showed that antibodies from the vaccines were able to neutralise Delta "so these are very reassuring news." ETXStudiopic
TWO doses of COVID vaccine appear to provide protection against the rapidly spreading Delta variant, the European Medicines Agency said.
The upbeat assessment came as the World Health Organization warned that the coronavirus variant first spotted in India could fuel a new wave of cases in Europe.
The EMA's head of vaccine strategy, Marco Cavaleri, said the Amsterdam-based watchdog was "aware of concerns caused by the rapid spread of the Delta variant.
"Right now it seems that the four vaccines approved in the European Union are protecting against all the strains circulating in Europe, including the Delta variant," he said.
"Emerging data from real world evidence are showing that two doses of vaccines are protective against the Delta variant."
Lab tests also showed that antibodies from the vaccines were able to neutralise Delta "so these are very reassuring news."
Four vaccines are currently approved for use in the EU: Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson.
But while the EU has been stepping up its vaccination programme, the WHO warned that cases are on the rise again after two months of decline.
The WHO said the reversal came as the Delta variant was overtaking the original Alpha variant that emerged in Britain "very quickly".
The EMA's Cavaleri said the regulator urged manufacturers to keep checking that their jabs were effective against all new variants of the disease including the so-called 'Delta Plus'.
"There are a number of variants that have been emerging over the last months, and we expect more to come over," Cavaleri said.
"Now there is the so-called Delta Plus variant, which is the Delta variant with an additional mutation in the spike protein, that is also important and we need to check that as well."
#Delta variant
#EMA
#Marco Cavaleri
#EU
#Pfizer-BioNTech
#Moderna
#AstraZeneca
#Johnson & Johnson
#English News